Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-01-04FDA Approved: PROZAC — Supplemental Application (Dista Products Company)
FDA approved a supplemental application for PROZAC (fluoxetine hydrochloride) submitted by Dista Products Company.
-
FDA label_change · 2017-01-04FDA Approved: EFFEXOR XR — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental labeling change for Effexor XR (venlafaxine hydrochloride) submitted by Viatris Specialty LLC. The supplemental …
-
FDA approval · 2017-01-04FDA Approved: FLUOXETINE — Supplemental Application (Dr.Reddy's Laboratories Limited)
FDA approved a supplemental application for fluoxetine from Dr. Reddy's Laboratories Limited.
-
FDA approval · 2017-01-04FDA Approved: CELEXA — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for CELEXA (citalopram) from Allergan, Inc. The notice does not specify the exact nature of the …
-
FDA approval · 2017-01-04FDA Approved: LEXAPRO — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for Lexapro (escitalopram) filed by Allergan, Inc. This is a supplemental approval of the NDA.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-01-04FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Vertical Pharmaceuticals, LLC)
The FDA approved a supplemental application for venlafaxine hydrochloride from Vertical Pharmaceuticals, LLC, likely related to labeling cha…
-
FDA approval · 2017-01-04FDA Approved: VENLAFAXINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for Venlafaxine from Sun Pharmaceutical Industries, Inc., indicating approval of a change to the exi…
-
FDA approval · 2017-01-04FDA Approved: VENLAFAXINE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental ANDA for venlafaxine by Heritage Pharmaceuticals (Avet) to bring a generic version to the market.
-
FDA approval · 2017-01-04FDA Approved: VENLAFAXINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for venlafaxine hydrochloride (generic venlafaxine) from Aurobindo Pharma Limited.
-
FDA approval · 2017-01-04FDA Approved: VENLAFAXINE — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA approved a supplemental application for Venlafaxine from Alembic Pharmaceuticals Inc. under an approved ANDA.
-
FDA approval · 2017-01-04FDA Approved: VIIBRYD — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for VIIBRYD (vilazodone hydrochloride) from Allergan, Inc., authorizing changes to the product label…
-
FDA label_change · 2017-01-04FDA Approved: FETZIMA — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for FETZIMA (levomilnacipran hydrochloride) from Allergan, Inc., authorizing a change to its labelin…
-
FDA approval · 2017-01-04FDA Approved: FLUOXETINE — Supplemental Application (Lannett Company, Inc.)
The FDA approved a supplemental application for a generic fluoxetine hydrochloride product manufactured by Lannett Company, Inc.
-
FDA approval · 2017-01-04FDA Approved: PRISTIQ EXTENDED-RELEASE — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
The FDA approved a supplemental application to approve Pristiq Extended-Release (desvenlafaxine succinate) as a new extended-release formula…
-
FDA approval · 2017-01-04FDA Approved: VENLAFAXINE — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application from BluePoint Laboratories for Venlafaxine (venlafaxine hydrochloride), a generic antidepressan…
-
FDA approval · 2017-01-04FDA Approved: CITALOPRAM — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for citalopram from Hikma Pharmaceuticals USA Inc.
-
CLINICAL_TRIALS trial_result · 2017-01-04Clinical Trial Update: Brain GABA Levels and Treatment Response in Major Depressive Disorder [Phase 4]
A Phase 4 clinical trial conducted at Massachusetts General Hospital evaluated brain GABA levels and treatment response in individuals with …
-
CLINICAL_TRIALS trial_result · 2017-01-04Clinical Trial Update: Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram [Phase 4]
Phase 4 study evaluating brain energy metabolism in adults with major depressive disorder treated with escitalopram; results have been poste…
-
FDA approval · 2017-01-04FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for venlafaxine hydrochloride (venlafaxine HCl) from Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2017-01-04FDA Approved: FLUOXETINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approves a supplemental application from Aurobindo Pharma Limited to market a generic fluoxetine product.
-
FDA approval · 2017-01-04FDA Approved: FLUOXETINE — Supplemental Application (Saptalis Pharmaceuticals, LLC.)
FDA approved a supplemental application for fluoxetine submitted by Saptalis Pharmaceuticals, LLC.
-
CLINICAL_TRIALS research · 2017-01-04Clinical Trial Update: The Experience of Older Adults Facing Depression for the First Time in Old Age
This report provides an update on a clinical study exploring how older adults experience a first-time episode of major depressive disorder i…
-
FDA approval · 2017-01-04FDA Approved: FLUOXETINE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
The FDA approved a supplemental application for a generic Fluoxetine hydrochloride product from PAI Holdings dba PAI Pharma under ANDA 07601…
-
CLINICAL_TRIALS trial_result · 2017-01-02Clinical Trial Update: Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives [Phase 2]
Phase 2 trial comparing continuous versus interrupted oral contraceptives for menstrually related disorders was terminated. Results were pos…
-
CLINICAL_TRIALS trial_result · 2016-12-29Clinical Trial Update: A Health Intervention to Prevent Depression Hepatitis C Patients [Phase 2, Phase 3]
The Phase 2/Phase 3 trial evaluating a health intervention to prevent depression in patients with Hepatitis C has been terminated.